Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era.
作者信息
Thanarajasingam Gita, Maurer Matthew J, Farooq Umar, Johnston Patrick B, Thompson Carrie A, Bennani Nabila N, Ansell Stephen M, Porrata Luis F, Macon William R, Syrbu Sergei I, Cerhan James R, Habermann Thomas M, Link Brian K, Witzig Thomas E, Nowakowski Grzegorz S
机构信息
Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
出版信息
Br J Haematol. 2018 Oct;183(1):149-152. doi: 10.1111/bjh.14922. Epub 2017 Sep 29.
Abstract
摘要
相似文献
1
Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era.24个月无事件生存可反映免疫化疗时代系统性弥漫性大B细胞淋巴瘤的中枢神经系统复发情况。
Br J Haematol. 2018 Oct;183(1):149-152. doi: 10.1111/bjh.14922. Epub 2017 Sep 29.
2
Successful chimeric antigen receptor T cell therapy in a case of primary testicular diffuse large-B-cell lymphoma with central nervous system progression.原发性睾丸弥漫性大B细胞淋巴瘤伴中枢神经系统进展患者的嵌合抗原受体T细胞疗法成功案例。
Leuk Lymphoma. 2019 Nov;60(11):2814-2816. doi: 10.1080/10428194.2019.1605507. Epub 2019 May 14.
3
Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure<sup/>.原发性乳腺弥漫性大B细胞淋巴瘤：治疗策略与失败模式
Leuk Lymphoma. 2018 Dec;59(12):2896-2903. doi: 10.1080/10428194.2018.1460825. Epub 2018 Apr 26.
4
Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study.血清乳酸脱氢酶高度升高与弥漫性大B细胞淋巴瘤患者的中枢神经系统复发相关：一项多中心前瞻性队列研究的结果
Oncotarget. 2016 Nov 1;7(44):72033-72043. doi: 10.18632/oncotarget.12459.
5
New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.弥漫性大B细胞淋巴瘤患者中枢神经系统复发的新危险因素及新趋势：一项回顾性研究
Chin J Cancer. 2016 Sep 13;35(1):87. doi: 10.1186/s40880-016-0150-y.
6
Central Nervous System Lymphoma.中枢神经系统淋巴瘤。
Hematol Oncol Clin North Am. 2019 Aug;33(4):597-611. doi: 10.1016/j.hoc.2019.03.008. Epub 2019 May 10.
7
Central nervous system relapse in patients with diffuse large B-cell lymphoma: analysis of incidence and prognostic factors.弥漫性大B细胞淋巴瘤患者的中枢神经系统复发：发病率及预后因素分析
Leuk Lymphoma. 2015 Jun;56(6):1869-71. doi: 10.3109/10428194.2014.969261. Epub 2014 Nov 5.
8
Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era.弥漫性大B细胞淋巴瘤累及睾丸：利妥昔单抗时代的预后及中枢神经系统复发风险
Br J Haematol. 2017 Jan;176(2):210-221. doi: 10.1111/bjh.14392. Epub 2016 Oct 14.
9
[Isolated central nervous system relapse of diffuse large B-cell lymphoma in the era of immunochemotherapy].[免疫化疗时代弥漫性大B细胞淋巴瘤的孤立性中枢神经系统复发]
Acta Med Croatica. 2012 Dec;66(5):403-7.
10
Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.利妥昔单抗时代弥漫大 B 细胞淋巴瘤患者中枢神经系统（CNS）预防对 CNS 复发的发生率和危险因素的影响：单中心经验和文献复习。
Br J Haematol. 2012 Oct;159(1):39-49. doi: 10.1111/j.1365-2141.2012.09247.x. Epub 2012 Jul 31.
引用本文的文献
1
SOHO State of the Art Updates and Next Questions: Prophylaxis and Management of Secondary CNS Lymphoma.SOHO 最新进展及后续问题：中枢神经系统淋巴瘤的预防和治疗。
Clin Lymphoma Myeloma Leuk. 2022 Oct;22(10):709-717. doi: 10.1016/j.clml.2022.06.002. Epub 2022 Jun 6.
2
CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies.来那度胺联合 R-CHOP（R2CHOP）治疗弥漫性大 B 细胞淋巴瘤（DLBCL）患者的中枢神经系统（CNS）复发：来自两项 2 期研究的分析。
Blood Cancer J. 2018 Jun 26;8(7):63. doi: 10.1038/s41408-018-0097-0.
3
Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.291 例弥漫性大 B 细胞淋巴瘤继发中枢神经系统侵犯患者的治疗策略、结局和预后因素。
Eur J Cancer. 2018 Apr;93:57-68. doi: 10.1016/j.ejca.2018.01.073. Epub 2018 Feb 21.
本文引用的文献
1
Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse.伊布替尼在中枢神经系统复发的套细胞淋巴瘤患者中的活性。
Blood. 2015 Oct 1;126(14):1695-8. doi: 10.1182/blood-2015-05-647834. Epub 2015 Aug 3.
2
Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.来那度胺联合 R-CHOP 克服了新诊断弥漫性大 B 细胞淋巴瘤中非生发中心 B 细胞表型的不良预后影响：一项 II 期研究。
J Clin Oncol. 2015 Jan 20;33(3):251-7. doi: 10.1200/JCO.2014.55.5714. Epub 2014 Aug 18.
3
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.伊布替尼联合利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松（R-CHOP）治疗初治 CD20 阳性 B 细胞非霍奇金淋巴瘤患者：一项非随机、1b 期研究。
Lancet Oncol. 2014 Aug;15(9):1019-26. doi: 10.1016/S1470-2045(14)70311-0. Epub 2014 Jul 17.
4
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.在接受免疫化疗治疗的弥漫性大 B 细胞淋巴瘤患者中，24 个月时无事件生存是疾病相关结局的一个强有力的终点。
J Clin Oncol. 2014 Apr 1;32(10):1066-73. doi: 10.1200/JCO.2013.51.5866. Epub 2014 Feb 18.
5
Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database.利妥昔单抗时代弥漫性大 B 细胞淋巴瘤中枢神经系统预防的益处缺失：来自大型国家数据库的结果。
Cancer. 2012 Jun 1;118(11):2944-51. doi: 10.1002/cncr.26588. Epub 2011 Oct 17.
6
Prevention of CNS relapse in diffuse large B-cell lymphoma.预防弥漫性大 B 细胞淋巴瘤中枢神经系统复发。
Lancet Oncol. 2011 Dec;12(13):1258-66. doi: 10.1016/S1470-2045(11)70140-1. Epub 2011 Sep 18.
7
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.LNH-98.5 试验患者的长期预后，这是第一项比较利妥昔单抗-CHOP 与 DLBCL 患者标准 CHOP 化疗的随机研究：成人淋巴瘤研究组的一项研究。
Blood. 2010 Sep 23;116(12):2040-5. doi: 10.1182/blood-2010-03-276246. Epub 2010 Jun 14.
8
Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy.弥漫性大 B 细胞淋巴瘤患者中枢神经系统复发的发生率和危险因素：利妥昔单抗联合 CHOP 化疗的影响。
Ann Oncol. 2010 May;21(5):1046-52. doi: 10.1093/annonc/mdp432. Epub 2009 Oct 27.
9
Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group.侵袭性非霍奇金淋巴瘤患者中枢神经系统复发的自然史：西南肿瘤学组（SWOG 8516）的20年随访分析
J Clin Oncol. 2009 Jan 1;27(1):114-9. doi: 10.1200/JCO.2008.16.8021. Epub 2008 Dec 1.
10
Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).侵袭性淋巴瘤中枢神经系统复发的发病率及危险因素——对德国高级别非霍奇金淋巴瘤研究组（DSHNHL）方案治疗的1693例患者的调查
Ann Oncol. 2007 Jan;18(1):149-157. doi: 10.1093/annonc/mdl327. Epub 2006 Oct 3.
Zotero 插件